Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response
- PMID: 8494709
- PMCID: PMC1968458
- DOI: 10.1038/bjc.1993.205
Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response
Abstract
Plasma sIl-2R and sCD8 levels of 12 patients with renal cell carcinoma were determined before and during subcutaneous rIl-2 therapy. Patients with a complete/partial remission showed a significantly stronger initial increase of sCD8 compared to patients with stable disease or tumour progression.
Similar articles
-
HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients.Cancer Immunol Immunother. 1993;36(3):198-204. doi: 10.1007/BF01741092. Cancer Immunol Immunother. 1993. PMID: 8439981 Free PMC article. Clinical Trial.
-
Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study.Ann Rheum Dis. 1994 Apr;53(4):235-9. doi: 10.1136/ard.53.4.235. Ann Rheum Dis. 1994. PMID: 8203951 Free PMC article.
-
Elevated soluble CD8 antigen and soluble interleukin-2 receptors in the sera of patients with juvenile rheumatoid arthritis.Clin Immunol Immunopathol. 1993 Jul;68(1):64-7. doi: 10.1006/clin.1993.1096. Clin Immunol Immunopathol. 1993. PMID: 8513595
-
Aldesleukin for metastatic renal cell carcinoma?Drug Ther Bull. 1993 Apr 13;31(8):29-30. Drug Ther Bull. 1993. PMID: 8348884 Review. No abstract available.
-
Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.Cancer J Sci Am. 1997 Dec;3 Suppl 1:S73-8. Cancer J Sci Am. 1997. PMID: 9457399 Review.
Cited by
-
Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU.Urol Res. 1996;24(5):297-303. doi: 10.1007/BF00304780. Urol Res. 1996. PMID: 8931295
-
Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.Drugs. 1993 Sep;46(3):446-514. doi: 10.2165/00003495-199346030-00009. Drugs. 1993. PMID: 7693434 Review.
-
The immunobiological effects of interleukin-2 in vivo.Cancer Immunol Immunother. 1994 Oct;39(4):207-16. doi: 10.1007/BF01525983. Cancer Immunol Immunother. 1994. PMID: 7954522 Free PMC article. Review. No abstract available.
-
Low on-treatment levels of serum soluble CD8 (sCD8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab.Cancer Immunol Immunother. 2023 Jun;72(6):1853-1863. doi: 10.1007/s00262-023-03377-8. Epub 2023 Jan 23. Cancer Immunol Immunother. 2023. PMID: 36688998 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical